Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RUDOLF J KOTULA

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1063477834
CMS profile
139221
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$32,641.69

129 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RUDOLF J KOTULA

NPI 1063477834 · CMS profile ID 139221

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063477834?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RUDOLF J KOTULA, NPI 1063477834, CMS profile ID 139221. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063477834?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RUDOLF J KOTULA, NPI 1063477834, CMS profile ID 139221. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063477834?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RUDOLF J KOTULA, NPI 1063477834, CMS profile ID 139221, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–129 of 129 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1063477834?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

129 matching records · $32,641.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 129 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–129 of 129.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Insmed, Inc. $19.3903/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089572936 CMS
PFIZER INC. $15.0603/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131267745 CMS
ViiV Healthcare Company $13.2103/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112718170 CMS
ABBVIE INC. $7.1403/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104103342 CMS
Takeda Pharmaceuticals U.S.A., Inc. $121.8003/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137607375 CMS
ABBVIE INC. $9.0603/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104103340 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.4802/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137607371 CMS
Gilead Sciences, Inc. $46.7402/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820547 CMS
Gilead Sciences, Inc. $47.1902/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820549 CMS
Gilead Sciences, Inc. $232.2302/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133868510 CMS
Gilead Sciences, Inc. $400.0002/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133868512 CMS
Gilead Sciences, Inc. $2,878.0602/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133868514 CMS
Gilead Sciences, Inc. $19.7802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820545 CMS
ViiV Healthcare Company $31.2002/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112805409 CMS
Gilead Sciences, Inc. $5.1702/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820541 CMS
Gilead Sciences, Inc. $16.0902/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820543 CMS
ViiV Healthcare Company $124.6902/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1112725614 CMS
Gilead Sciences, Inc. $3,240.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133607794 CMS
Astellas Pharma US Inc $23.9802/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139292486 CMS
ABBVIE INC. $26.0102/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104103338 CMS
Merck Sharp & Dohme LLC $21.5202/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141622533 CMS
Gilead Sciences, Inc. $20.6301/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133820539 CMS
Paratek Pharmaceuticals, Inc. $17.4201/24/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1113906753 CMS
Merck Sharp & Dohme LLC $21.8601/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141919056 CMS
Takeda Pharmaceuticals U.S.A., Inc. $29.9001/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137607367 CMS
CSL Behring $28.8601/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134605313 CMS
AIMMUNE THERAPEUTICS, INC. $38.3301/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147021167 CMS
Insmed, Inc. $21.3401/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089575294 CMS
Ferring Pharmaceuticals Inc. $16.8201/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137488253 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,809.11 88
PY2020 $11,366.58 45
PY2021 $23,980.10 45
PY2022 $43,544.75 77
PY2023 $53,063.06 114
PY2024 $32,641.69 129
PY2025 $53,689.60 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $97,084.00 15
PY2020 Principal investigator $95,461.18 4
PY2019 Principal investigator $106,835.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $6,000.00 12/13/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517389
Principal investigator 1 SANOFI PASTEUR INC. $14,835.00 10/06/2021 Non-covered Recipient Entity
Methodist Physicians Clinic Infectious Disease
STA00011 Stamaril Yellow Fever No dispute reported 06/30/2026 838360767
Principal investigator 1 Gilead Sciences, Inc. $250.00 09/20/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517387
Principal investigator 1 Gilead Sciences, Inc. $480.00 09/13/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517385
Principal investigator 1 Gilead Sciences, Inc. $3,360.00 08/16/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517383
Principal investigator 1 Gilead Sciences, Inc. $250.00 08/09/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517379
Principal investigator 1 Gilead Sciences, Inc. $250.00 08/09/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517381
Principal investigator 1 Gilead Sciences, Inc. $5,200.00 05/19/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517375
Principal investigator 1 Gilead Sciences, Inc. $20,309.00 05/19/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517377
Principal investigator 1 Gilead Sciences, Inc. $275.00 05/03/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517373
Principal investigator 1 SANOFI PASTEUR INC. $7,500.00 04/27/2021 Non-covered Recipient Entity
Quality Clinical Research Inc
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent) No dispute reported 06/30/2026 838357943
Principal investigator 1 Gilead Sciences, Inc. $17,611.00 04/26/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517371
Principal investigator 1 SANOFI PASTEUR INC. $1,750.00 04/06/2021 Non-covered Recipient Entity
Quality Clinical Research Inc
Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent) No dispute reported 06/30/2026 838357931
Principal investigator 1 Eli Lilly and Company $7,150.00 02/22/2021 Non-covered Recipient Entity
THE NEUROLOGY RESEARCH GROUP LLC
A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND, SPONSOR UNBLINDED, SINGLE ASCENDING DOSE, PHASE 1 FIRST IN HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVENOUS LY3819253 IN PARTICIPANTS HOSPITALIZED FOR COVID 19 No dispute reported 06/30/2026 819467703
Principal investigator 1 Gilead Sciences, Inc. $11,864.00 02/01/2021 Non-covered Recipient Entity
QUALITY CLINICAL RESEARCH INC
Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) treatment of COVID-19 in an outpatient setting No dispute reported 06/30/2026 803517369